ARCHIVES

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 32 No. 12 | December 25, 2009

Download PDF Visit The Full Archive

Related Articles

NCI Puts Aside Fear Of Brockovich Factor To Open New Web Site On Mortality Data.

April 20, 2001

NCI Reportedly Gets $691 Million From House, Senate Conferees

October 4, 1974

Cvitkovic Responds To Story On March ODAC Meeting.

June 23, 2000

NCI Progress: Biomarker Labratories Funded To Develop Early Detection Methods

October 22, 1999

Research Dollars Save Money, Lives, Scientists Tell Senate

May 3, 1991

Cancer Control Planning Completed, Going Through Final Review Process

July 12, 1974